In addition to promoting weight loss [479,480,481,482,483], peripherally selective CB1R antagonist/inverse agonist also demonstrated improvements in metabolic profiles [465,484,485] and liver function [486] in preclinical studies, thereby further highlighting the therapeutic utility of targeting the peripheral CB1R in metabolic syndromes. This evidence concerns the gene CNR1 and metabolic syndrome.